Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Justyna Kelly as Chief Operating Officer

POINT Biopharma Global Inc., a Delaware corporation (together with its wholly owned subsidiaries, "POINT" or the "Company"), today announced the appointment of Justyna Kelly, previously the Vice President, Medical Isotope Development and Operations of the Company, as the Company's Chief Operating Officer, effective as of December 1, 2021.

Ms. Kelly, 37 has served as POINT's Vice President, Medical Isotope Development and Operations since November 2020. Ms. Kelly was responsible for all medical isotope development and operations related to clinical and commercial programs at the Company. Ms. Kelly has 11 years of radiopharmaceutical experience from the Centre for Probe Development and Commercialization (CPDC), where she led microbiology and sterility assurance programs, supported the build-out of clinical-stage GMP manufacturing facilities, and managed several internal and client radiopharmaceutical development programs. Ms. Kelly has expertise in working with a variety of medical isotopes, including sourcing, supply chain, development and manufacturing, and application to radiopharmaceutical manufacturing. Ms. Kelly earned a Bachelor of Science and Master of Science in biochemistry from McMaster University.

In connection with Ms. Kelly's appointment as Chief Operating Officer, Ms. Kelly entered into a new employment agreement with POINT Biopharma USA Inc. The employment agreement with Ms. Kelly provides for a base salary of $350,000 per year (subject to periodic adjustment as determined by the Company's board of directors (the "Board")), an annual incentive bonus of up to 37.5% of her base salary based upon the Board's determination that established performance objectives have been met by both POINT and Ms. Kelly and eligibility to participate in our benefits plans generally available to our other executives. Ms. Kelly will be eligible to receive a non-qualified option to purchase 70,000 shares of the Company's common stock, subject to the approval of the Board. Pursuant to her employment agreement, Ms. Kelly will be reimbursed for reasonable moving expenses, up to $45,000, and the reasonable cost of a short-term lease, up to $35,000, until she enters into a long-term lease or purchases a home. Further, the Company will reimburse Ms. Kelly up to $5,000 for the cost of a tax professional with respect to advice with preparation of her tax return for the year she moves to the United States. Ms. Kelly is entitled to certain severance benefits upon a termination of her employment by the Company without "cause" (as defined in the employment agreement), subject to her execution and delivery of a release of claims in favor of the Company in the form satisfactory to the Company, in the form of (i) a lump sum cash payment equal to 25% of her then current base pay plus 25% of her maximum target annual bonus; and (ii) so long as Ms. Kelly has been employed by the Company for three (3) consecutive years from the effective date of the employment agreement, an additional lump sum cash payment equal to one-twelfth (1/12th) of her then current salary multiplied by the number of full years of employment. Additionally, Ms. Kelly is entitled to certain benefits upon a termination of her employment by the Company without "cause" (as defined in the employment agreement) within 30 days prior to or within 12 months after a "change of control" (as defined in the employment agreement), subject to her execution and delivery of a release of claims in favor of POINT in the form satisfactory to POINT, in the form of (i) a lump sum


--------------------------------------------------------------------------------

cash payment equal to 50% of her then current salary plus 50% of the maximum target annual bonus; and (ii) so long as Ms. Kelly has been employed by the Company for three (3) consecutive years from the effective date of the employment agreement, an additional lump sum cash payment equal to one-twelfth (1/12th) of her then current salary multiplied by the number of full years of employment. In addition, any unvested stock options granted to Ms. Kelly will vest and be exercisable upon a change in control. Ms. Kelly's employment agreement also contains non-compete obligations within the United States and Canada during its term and for six months thereafter and non-solicit obligations for 18 months thereafter.

There are no arrangements or understandings between Ms. Kelly and any other persons pursuant to which she was selected as the Company's Chief Operating Officer. There are no family relationships between Ms. Kelly and any director or executive officer of the Company, and Ms. Kelly has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Departure of Michael Gottlieb as Chief Commercial Officer

On November 25, 2021, Michael Gottlieb, the Chief Commercial Officer of the Company, ceased his service to the Company. In connection with this event, Mr. Gottlieb is entitled to certain severance payments as provided under his employment agreement with the Company.

A copy of the press release announcing the appointment of Ms. Kelly and the departure of Mr. Gottlieb is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.
Number     Exhibit
99.1       Press Release, dated December 1 2021  .
104     Cover Page Interactive Data File (embedded within the Inline XBRL
document).

© Edgar Online, source Glimpses